RECRUITING

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Description

The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: * are adults of 18 years of age or older. * are confirmed to have CLE or SLE with involvement of the skin. * have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins). At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60. The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period.

Conditions

Lupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Talk to us

Related Conditions:

Lupus Erythematosus, SystemicLupus Erythematosus, Cutaneous

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: * are adults of 18 years of age or older. * are confirmed to have CLE or SLE with involvement of the skin. * have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins). At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60. The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period.

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF-06823859 IN ADULT PARTICIPANTS WITH ACTIVE CLE OR SLE WITH CUTANEOUS MANIFESTATIONS

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Condition
Lupus Erythematosus, Systemic
Intervention / Treatment

-

Contacts and Locations

Birmingham

The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States, 35233

Birmingham

University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States, 35233

Birmingham

University of Alabama at Birmingham, Department of Dermatology, Birmingham, Alabama, United States, 35233

Birmingham

The University of Alabama at Birmingham, Birmingham, Alabama, United States, 35249

Phoenix

Mayo Clinic Hospital, Phoenix, Arizona, United States, 85054

Scottsdale

Mayo Clinic in Arizona - Scottsdale, Scottsdale, Arizona, United States, 85259

Los Angeles

Dermatology Research Associates, Los Angeles, California, United States, 90045

Jacksonville

Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224

Atlanta

Emory University, Atlanta, Georgia, United States, 30322

Sandy Springs

Advanced Medical Research, PC., Sandy Springs, Georgia, United States, 30328

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have a histologically confirmed active CLE or SLE with cutaneous manifestations in the form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneous lupus erythematosus at least 3 months and CLASI-A at least 8 or higher.
  • * Participant has adequate intravenous infusion access per investigator's judgement
  • * Willing to comply with study procedures including skin punch biopsies procedures.
  • * Weight is greater than 40 kg and less than 130 kg.
  • * Skin disorders other than CLE or SLE.
  • * Active, severe lupus nephritis requiring treatment with cytotoxic agents or high-dose steroids.
  • * Active severe central nervous system lupus requiring therapeutic intervention within 60 days of baseline.
  • * Cancer or a history of cancer within 5 years of screening except adequately resected basal or squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix.
  • * Known history of a major cardiovascular or cerebrovascular event within 24 months, pulmonary arterial hypertension, pulmonary embolism within 6 months of screening.
  • * Have any autoimmune or inflammatory disease that would interfere with interpretation of test results or clinical assessments.
  • * History of disseminated herpes zoster/simplex or recurrent herpes zoster.
  • * Serious infection within 60 days of baseline or an active infection treated with oral antibiotics within 14 days of baseline.
  • * Have evidence of active or latent infection of hepatitis B or C, known history of human immunodeficient virus (HIV) infection, or infected with Mycobacterium TB (active or latent TB)
  • * Laboratory abnormalities that meet exclusion criteria at the Screening visit. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Pfizer,

Pfizer CT.gov Call Center, STUDY_DIRECTOR, Pfizer

Study Record Dates

2026-11-18